Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs
- 29 October 2025
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (6) , 2054-2072
Abstract
The blood-brain barrier (BBB), crucial for central nervous system (CNS) homeostasis, poses challenges for drug delivery in CNS diseases due to selective permeability. Because of this difficulty, there are limited treatments developed for CNS diseases. As a solution, computational models can be implemented in treatment development to enable rapid screening of drug permeability, saving time and resources. This study explores machine learning, deep learning, and transfer learning models to predict the BBB permeability of drug molecules, validated through an in vitro assay known as Parallel Artificial Membrane Permeability Assay-BBB (PAMPA-BBB). Using the Blood-Brain Barrier Database (B3DB) of ∼ 8,000 compounds of known BBB permeability, classification models including support vector machines (SVMs), deep neural networks (DNNs), direct message passing neural networks (D-MPNNs), and transfer learning with quantum chemical properties were developed. Experimental validation with 18 compounds from the Emory Enriched Bioactive Library (EEBL), a library containing 1,018 FDA-approved pharmacologically active compounds of known activity, highlighted PAMPA-BBB as a robust validation method. The SVM model with combined 2D RDKit and Morgan fingerprint molecular representation achieved high performance (accuracy: 89.08%) on the B3DB test set. The best-performing models for the 18 EEBL compounds were transfer learning models. In particular, the model trained on the QM9-extended polarizability property correctly classified 17 out of 18 compounds, while the model trained on the QM9-extended dipole moment property achieved correct classification across all 18 experimental compounds. Additional analyses demonstrated that QC-based transfer learning provides complementary predictive value beyond traditional molecular descriptors such as LogP and molecular weight. QC-pretrained models achieved higher accuracy and ROC-AUC on both the B3DB and external PAMPA test sets, with performance remaining robust even after descriptor ablation. Moreover, QC-pretrained models outperformed the baseline of P-glycoprotein (P-gp) inhibition, underscoring the unique contribution of quantum-derived representations to BBB permeability prediction. Therefore, this study motivates the synergy of computational and experimental methods in enabling faster, more cost-effective, and targeted identification of CNS-active or CNS-sparing drugs.Keywords
Funding Information
- National Cancer Institute, Cairo University (R01CA251393)
- NIH (R25GM143298)
- Georgia Clinical and Translational Science Alliance (UL1TR002378)
- Georgia Clinical and Translational Science Alliance (KL2TR002381)
This publication has 54 references indexed in Scilit:
- BMY 7378, a selective α1D-adrenoceptor antagonist, is a new angiotensin converting enzyme inhibitor: In silico, in vitro and in vivo approachBiochimica et Biophysica Acta (BBA) - General Subjects, 2024
- The barrier and interface mechanisms of the brain barrier, and brain drug deliveryBrain Research Bulletin, 2022
- Factors influencing the blood-brain barrier permeabilityBrain Research, 2022
- In Vitro Human Blood-Brain Barrier Model for Drug Permeability Testing2021
- Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategiesActa Pharmaceutica Sinica B, 2020
- Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directionsMedicinal Research Reviews, 2020
- Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug moleculesBrain Research Bulletin, 2020
- HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune EnhancersCell Chemical Biology, 2019
- Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the artBiomedicine & Pharmacotherapy, 2018
- Antimicrobial Drugs2006